A Study of the Safety and Pharmacokinetics of AGS-22M6E in Subjects With Malignant Solid Tumors That Express Nectin-4

PHASE1CompletedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

July 11, 2011

Primary Completion Date

April 27, 2015

Study Completion Date

April 27, 2015

Conditions
TumorsMedical OncologyNeoplasms
Interventions
DRUG

AGS-22M6E

IV Infusion

DRUG

ASG-22CE

IV Infusion

Trial Locations (9)

10021

Memorial Sloan Kettering Cancer Center, New York

14263

Roswell Park Cancer Institute, Buffalo

27599

University of North Carolina, Chapel Hill, Chapel Hill

30322

Emory University, Atlanta

48201

Karmanos Cancer institute, Detroit

80045

University of Colorado, Denver-Aurora, Aurora

94115

UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco

02115

Dana-Farber Cancer Institute, Boston

T6G 1Z2

Cross Cancer Institute, Edmonton

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Agensys, Inc.

INDUSTRY

collaborator

Seagen Inc.

INDUSTRY

lead

Astellas Pharma Inc

INDUSTRY